Gastric Cancer Breakthrough
China has developed the world's first oral vaccine for Helicobacter pylori (HP), a bacterium closely linked to gastric cancer. The vaccine is designed to prevent infection by HP that inhabits parts of the stomach, believed to be strongly linked to the development of duodenal and gastric ulcers and even stomach cancer.
This is the world's first HP vaccine to finish large-scale phase-three clinical trials and become ratified as a new medicine. The vaccine has been classified as a "first-grade new medicine" by the State Food and Drug Administration, China's drug watchdog.
It was developed by a research team from the Chongqing-based Third Military Medical University. During the research process, the vaccine secured eight national patents and now has full independent intellectual property rights. Clinical research shows that the vaccine has a protection rate of more than 72.1 percent against HP. |